<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03921411</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.116912</org_study_id>
    <nct_id>NCT03921411</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)</brief_title>
  <official_title>A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics and Safety of Nemolizumab (CD14152) in Adolescent Subjects (12-17 Years) With Moderate-to-Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asses the pharmacokinetics and safety of nemolizumab in adolescent subjects with AD.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nemolizumab serum concentration in adolescent subjects</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events, including TEAEs, AESIs and SAEs</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects who have a change from baseline in physical examinations (normal to abnormal) at each visit</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>A complete physical exam includes:
Head, ears, eyes, nose, throat, neck (including thyroid)
Skin/integumentary system
Cardiovascular system
Respiratory system
Gastrointestinal system
Musculoskeletal system
Lymph nodes
Nervous system
Respiratory exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects who have a change from baseline in vital signs (normal to abnormal) at each visit</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Vital signs includes:
Systolic Blood Pressure
Diastolic Blood Pressure
Pulse Rate
Temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects who have clinically significant laboratory abnormalities in hematology, blood chemistry, or urinalysis results at each visit</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects who have a clinically significant abnormal ECG</measure>
    <time_frame>Screening to Week 16</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Nemolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nemolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nemolizumab</intervention_name>
    <description>Nemolizumab</description>
    <arm_group_label>Nemolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria

          -  Male or female subjects ≥ 12 to &lt; 17 years of age

          -  Chronic AD that has been documented for at least 2 years

          -  Eczema Area and Severity Index (EASI) score ≥ 16

          -  IGA score ≥ 3

          -  AD involvement ≥ 10% of Body Surface Area (BSA)

          -  Documented recent history of inadequate response to topical medications

          -  Women of childbearing potential must agree to be strictly abstinent or to use an
             effective and approved method of contraception throughout the study and for 12 weeks
             after the last study drug injection.

        Key Exclusion Criteria

          -  Body weight &lt; 30 kg

          -  Cutaneous infection within 1 week or any infection requiring treatment with oral or
             parenteral antibiotics, antivirals, antiparasitics, or antifungals within 1 week

          -  History of hypersensitivity (including anaphylaxis) to an immunoglobulin product
             (plasma-derived or recombinant, eg, monoclonal antibody)

          -  Any clinically significant issue, based investigator judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230-5806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

